Biogen

YTD

ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

27.20B

Market cap27.20B

Price-Earnings ratio

21.03

Price-Earnings ratio21.03

Dividend yield

—

Dividend yield—

Average volume

928.91K

Average volume928.91K

High today

$186.27

High today$186.27

Low today

$182.60

Low today$182.60

Open price

$183.99

Open price$183.99

Volume

197.45K

Volume197.45K

52 Week high

$202.41

52 Week high$202.41

52 Week low

$110.04

52 Week low$110.04

Stock Snapshot

Biogen(BIIB) stock is priced at $185.36, giving the company a market capitalization of 27.2B. It carries a P/E multiple of 21.03.

On 2026-03-09, Biogen(BIIB) stock moved within a range of $182.60 to $186.27. With shares now at $185.36, the stock is trading +1.5% above its intraday low and -0.5% below the session's peak.

Trading activity shows a volume of 197.45K, compared to an average daily volume of 928.91K.

Over the past 52 weeks, Biogen(BIIB) stock has traded between a high of $202.41 and a low of $110.04.

BIIB News

Simply Wall St 2d

Biogen’s Dravet And SMA Advances Add Depth To Long Term Story

Biogen (NasdaqGS:BIIB) and Stoke Therapeutics reported promising clinical results for zorevunersen in Dravet syndrome, with data highlighting durable seizure re...

TipRanks 5d

Stoke Therapeutics, Biogen publish data from zorevunersen studies in NEJM

Stoke Therapeutics (STOK) and Biogen (BIIB) announced the publication of data from studies of the investigational medicine zorevunersen in The New England Journ...

Analyst ratings

56%

of 36 ratings

Buy

41.7%

Hold

55.6%

Sell

2.8%

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Pfizer

Taiwan Semiconductor Manu…

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.